Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05588193 · ClinicalTrials.gov registry record · NA

ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments

A NA study of HIV, sponsored by Albert Einstein College of Medicine.

Active
Registry status
NA
Development phase
1,560
Enrollment target
2
Study locations

NCT05588193: Active NA study of HIV, sponsored by Albert Einstein College of Medicine.

NCT05588193 is a NA study of HIV that is active but no longer recruiting, run by Albert Einstein College of Medicine. The registered enrollment target is 1,560 participants, above the 435-participant average among 303 other HIV trials with a reported enrollment target (259% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05588193, a NA study of HIV, is active but no longer recruiting, sponsored by Albert Einstein College of Medicine.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,560 participants
Enrollment target
2
Study locations

Study Summary

Severe inequities in HIV pre-exposure prophylaxis (PrEP) access and use in communities hardest hit by the HIV epidemic persist, further exacerbating ongoing racial/ethnic and socioeconomic disparities in HIV incidence. In these same communities, many patients at risk for HIV seek care for sexually transmitted infections (STIs) in Emergency Departments (EDs), but the structure of traditional ED care is poorly suited to address HIV prevention or provide PrEP. To advance the Prevent objective of the Ending the HIV Epidemic (EHE) initiative, ED2PrEP will leverage an implementation science approach to rigorously test two innovative strategies for increasing PrEP uptake among patients seeking STI care in EDs in one of the 48 EHE-identified geographic hotspots.

Primary Outcome

PrEP uptake will be defined as the percentage of participants not known to have HIV (either by HIV test result or self-reporting) AND who are prescribed any medication to be used as HIV PrEP, as captured in the electronic health record, within 3 months following visit to the emergency department (ED). The number/percentage of participants will be summarized by study arm. PrEP Uptake within 3 months will be used to evaluate the effectiveness of PrEP strategies.

Conditions Studied

Interventions

  • BEHAVIORAL PVO
  • BEHAVIORAL TSH

Study Locations (2)

New York

  • City University of New York - Hunter College - New York
  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 1,560 participants
Start Date 2024-10-01
Est. Completion 2026-11-13
Phase NA
Albert Einstein College of Medicine

175 total trials

What the registry record for NCT05588193 still lists

NCT05588193 is an interventional study that assigns participants to a tested intervention. Its 1,560 participants enrollment target places it among the larger protocols in the corpus, above the 435-participant average among 303 other HIV trials with a reported enrollment target (259% higher).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which PVO is the first listed.

NCT05588193 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05588193 about?

NCT05588193 is a clinical study titled "ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments". Severe inequities in HIV pre-exposure prophylaxis (PrEP) access and use in communities hardest hit by the HIV epidemic persist, further exacerbating ongoing racial/ethnic and socioeconomic disparities in HIV incidence. In these same communities, many patients at risk for HIV seek care for sexually t...

What is the current status of trial NCT05588193?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,560 participants. The study started on 2024-10-01. Estimated completion is 2026-11-13.

What conditions does trial NCT05588193 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT05588193?

The interventions under investigation include: PVO (BEHAVIORAL), TSH (BEHAVIORAL).

Who is sponsoring clinical trial NCT05588193?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05588193 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05588193's enrollment target sits among peer trials

1,560 12th of 303 higher than 292 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06881069 · 1,560 participants · NA

    Reach Through Equitable Implementation in Utah

  • NCT06034080 · 1,566 participants · NA

    Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections

  • NCT02650622 · 1,550 participants

    Genetic and Metabolic Disease in Children

  • NCT03961945 · 1,550 participants · NA

    Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05588193, the US trial registry maintained by the National Library of Medicine. NCT05588193 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.